


# Appendix

## TABLE OF CONTENTS


1. Appendix Figure S1
2. Appendix Figure S2
3. Appendix Figure S3
4. Appendix Figure S3 Legends
5. Appendix Figure S4

# Appendix Supplementary Figure 1



**Appendix Supplementary Figure 1.** (A) Western blot analysis of HeLa and TRIM16 CRISPR-CAS9 knock out clones. (B, C) Western blot analysis of control and TRIM16 siRNA transfected (B) HeLa cells (C) THP-1. L.E, Low exposure; H.E, High exposure. (D) Left panel, Representative confocal images of control and TRIM16 siRNA transfected cells, untreated or treated with MG132 (20  $\mu$ M, 2h), H<sub>2</sub>O<sub>2</sub> (200  $\mu$ M, 2h), and processed for immunofluorescence microscopy (IF) analysis with Ubiquitin (FK2) antibody. Right panel, HeLa and TRIM16<sup>KO</sup> cells were visualized and cells with more than 2 visible aggresomes/ALIS were considered positive. (E) Representative confocal images of control and TRIM16 siRNA transfected THP-1 cells treated with MG132 (20  $\mu$ M, 2h) and the samples were processed for IF analysis with FK2. (F) Representative confocal images HeLa and TRIM16<sup>KO</sup> cells treated with H<sub>2</sub>O<sub>2</sub> (200  $\mu$ M, 2h) and processed for IF analysis with Proteostat dye and p62 antibody.


# Appendix Supplementary Figure 2




**Appendix Supplementary Figure 2.** (A) Protein extracted from control and TRIM16 siRNA transfected cells are subjected to western blotting with indicated antibodies. (B) Western blot analysis of HeLa and TRIM16<sup>KO</sup> cell lysates probed with indicated antibodies. (C) Densitometric analysis (mean ±SD) of protein band intensity relative to Actin, n=3, \*p=0.05, (Student's unpaired t test). (D) RNA isolated from HeLa and TRIM16<sup>KO</sup> cells were subjected to quantitative to real-time PCR (qRT-PCR) with primers of p62, Keap1, and Nrf2. Data represent mean ±SD, n=3, \*p < 0.05; #insignificant. (E) IP analysis of interaction between endogenous TRIM16 and endogenous NRF2 in HeLa cell lysates in presence of MG132. (F) Co-IP analysis of interaction between TRIM16 and NRF2 in HEK-293T lysates of cells expressing GFP or GFP-TRIM16.

# Appendix Supplementary Figure 3


**A**




**B**




**C**




**D**




**E**




**F**




**G**





**H**




**I**



**J**



**K**




## Appendix Supplementary Figure 3


**Appendix Supplementary Figure 3.** (A, B) Analysis of GFP ubiquitination in absence and presence of TRIM16 by Co-IP assays using transiently transfected plasmid constructs as indicated. Two different variants of Ubiquitin protein are used, one that can only be ubiquitinated at Lysine 48 residue (HA-K48-UB) and other that can be only ubiquitinated at Lysine 63 residue (HA-K63-UB). All other lysine residues are mutated. (C) Western blot analysis of HeLa and TRIM16<sup>KO</sup> lysates of cells treated with H<sub>2</sub>O<sub>2</sub> for different durations as indicated and probed with indicated antibodies. (D, E) RNA isolated from cells, untreated or treated with MG132 (20 μM, 4h) for different durations and were subjected to qRT-PCR with primers of genes as indicated. The fold induction in MG132 treated samples is calculated relative to untreated samples. (F) Representative Confocal images of HeLa and TRIM16<sup>KO</sup> cells transiently expressing GFP-p62 and IF analysis is performed with Ub antibody. (G) Immunoprecipitation (IP) analysis of interaction between endogenous TRIM16 and endogenous LC3-II in HeLa cell lysates in absence (upper panel) and presence (lower panel) of MG132 (10 μM, 4h). \*The panel H here, Fig 2 panel J and Fig EV2 panel H are part of same blots hence the input for TRIM16 is same. L.E, Low exposure; H.E, High exposure. (H) WB analysis of lysates from HeLa cell which were either starved or not starved in absence and presence of Bafilomycin A1 (300 nM, 3h) with the antibodies as indicated. (I, J) MTT assays performed at different time points with HeLa and TRIM16<sup>KO</sup> cells untreated or treated with H<sub>2</sub>O<sub>2</sub> (400 μM, 2h) and MG132 (20 μM, 12h) (K) Immunoblot blot analysis of HeLa and TRIM16<sup>KO</sup> lysates of cells treated with 400 μM of H<sub>2</sub>O<sub>2</sub> for different durations as indicated and probed with antibodies as shown.

# Appendix Supplementary Figure 4

**A**



**B**



Appendix Supplementary Figure 4. (A) Body weight of mice throughout the experiment. (B) After the sacrifice of mice, tumors (n=6 for each group) were harvested and weighed (in grams). Graph, Mean ±SD, n=3, \*p < 0.05 (ANOVA).